Nicorandil attenuates monocrotaline-induced vascular endothelial damage and pulmonary arterial hypertension

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Sahara, Makoto ^a,c   Sata, Masataka ^b   Morita, Toshihiro ^a   Hirata, Yasunobu ^a   Nagai, Ryozo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CASPASE 3; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLIBENCLAMIDE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCROTALINE; N(G) NITROARGININE METHYL ESTER; NICORANDIL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; ANTIHYPERTENSIVE AGENT; ENZYME INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL SURVIVAL; CHANNEL GATING; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; HEART RIGHT VENTRICLE PRESSURE; HUMAN; HUMAN CELL; MALE; NONHUMAN; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; RIGHT VENTRICULAR SYSTOLIC PRESSURE; THROMBOEMBOLISM; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; VASCULAR ENDOTHELIUM; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG EFFECT; HEART VENTRICLE PRESSURE; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZATION; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

RATTUS;

ANIMALS; ANTIHYPERTENSIVE AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELLS, CULTURED; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; GLYBURIDE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPERTENSION, PULMONARY; INJECTIONS, INTRAPERITONEAL; MALE; MAP KINASE SIGNALING SYSTEM; MONOCROTALINE; NG-NITROARGININE METHYL ESTER; NICORANDIL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; VENTRICULAR PRESSURE;

EID: 84859131438     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033367     Document Type: Article

References (27)

1. Archer S, Rich S, (2000) Primary pulmonary hypertension: a vascular biology and translational research "Work in progress". Circulation 102: 2781-2791.
2. Humbert M, Sitbon O, Simonneau G, (2004) Treatment of pulmonary arterial hypertension. N Engl J Med 351: 1425-1436.
3. Rabinovitch M, (1997) Pulmonary hypertension: updating a mysterious disease. Cardiovasc Res 34: 268-272.
4. Voelkel NF, Cool C, (2004) Pathology of pulmonary hypertension. Cardiol Clin 22: 343-351.
5. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Maho G, et al. (2001) Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 15: 427-438.
6. Zhao YD, Campbell AI, Robb M, Ng D, Stewart DJ, (2003) Protective role of angiopoietin-1 in experimental pulmonary hypertension. Circ Res 92: 984-991.
7. Farkas L, Farkas D, Ask K, Möller A, Gauldie J, et al. (2009) VEGF ameliorates pulmonary.hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. J Clin Invest 119: 1298-1311.
8. Taira N, (1989) Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 63: 18J-24J.
9. Sato T, Sasaki N, O'Rourke B, Marban E, (2000) Nicorandil, a potent cardioprotective agent, acts by opening mitochondrial ATP-dependent potassium channels. J Am Coll Cardiol 35: 514-518.
10. Sahara M, Sata M, Morita T, Nakamura K, Hirata Y, et al. (2007) Diverse contribution of bone marrow-derived cells to vascular remodeling associated with pulmonary arterial hypertension and arterial neointimal formation. Circulation 115: 509-517.
11. Datta SR, Brunet A, Greenberg ME, (1999) Cellular survival: a play in three Akts. Genes Dev 13: 2905-2927.
12. Segar R, Krebs EG, (1995) The MAPK signaling cascade. FASEB J 9: 726-735.
13. IONA Study Group (2002) Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 359: 1269-1275.
14. Hongo M, Mawatari E, Sakai A, Ruan Z, Koizumi T, et al. (2005) Effects of nicorandil on monocrotaline-induced pulmonary arterial hypertension in rats. J Cardiovasc Pharmacol 46: 452-458.
15. Sahara M, Takahashi T, Imai Y, Nakajima T, Yao A, et al. (2006) New insights in the treatment strategy for pulmonary arterial hypertension. Cardiovasc Drugs Ther 20: 377-386.
16. Lame MW, Jones AD, Wilson DW, Dunston SK, Segall HJ, (2000) Protein targets of monocrotaline pyrrole in pulmonary artery endothelial cells. J Biol Chem 275: 29091-29099.
17. Fujiwara R, Hayashi T, Kutsumi Y, Oida K, Tamai T, et al. (1993) Effects of nicorandil on cell proliferation and cholesteryl ester accumulation in arterial smooth muscle cells in culture. Cardiovasc Drugs Ther 7: 365-372.
18. Tamosiuniene R, Tian W, Dhillon G, Wang L, Sung YK, et al. (2011) Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension. Circ Res 109: 867-879.
19. Akao M, Teshima Y, Marbán E, (2002) Antiapoptotic effect of nicorandil mediated by mitochondrial atp-sensitive potassium channels in cultured cardiac myocytes. J Am Coll Cardiol 40: 803-810.
20. Horinaka S, Kobayashi N, Higashi T, Hara K, Hara S, et al. (2001) Nicorandil enhances cardiac endothelial nitric oxide synthase expression via activation of adenosine triphosphate-sensitive K channel in rat. J Cardiovasc Pharmacol 38: 200-210.
21. Wang Y, Ahmed N, Wang B, Ashraf M, (2007) Chronic preconditioning: a novel approach for cardiac protection. Am J Physiol Heart Circ Physiol 292: H2300-H2305.
22. Guyton KZ, Liu Y, Gorospe M, Xu Q, Holbrook NJ, (1996) Activation of mitogen-activated protein kinase by H2O2. Role in cell survival following oxidant injury. J Biol Chem 271: 4138-4142.
23. Pain T, Yang XM, Critz SD, Yue Y, Nakano A, et al. (2000) Opening of mitochondrial KATP channels triggers the preconditioned state by generating free radicals. Circ Res 87: 460-466.
24. Xu Z, Ji X, Boysen PG, (2004) Exogenous nitric oxide generates ROS and induces cardioprotection: involvement of PKG, mitochondrial KATP channels, and ERK. Am J Physiol Heart Circ Physiol 286: H1433-H1440.
25. Ahmad N, Wang Y, Haider KH, Wang B, Pasha Z, et al. (2006) Cardiac protection by mitoKATP channels is dependent on Akt translocation from cytosol to mitochondria during late preconditioning. Am J Physiol Heart Circ Physiol 290: H2402-H2408.
26. Kasuno K, Takabuchi S, Fukuda K, Kizaka-Kondoh S, Yodoi J, et al. (2004) Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling. J Biol Chem 279: 2550-2558.
27. Malhotra R, Hess D, Lewis GD, Bloch KD, Waxman AB, et al. (2011) Vasoreactivity to inhaled nitric oxide with oxygen predicts long-term survival in pulmonary arterial hypertension. Pulm Circ 1: 250-258.